Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
Dundar Y, Bagust A, Hounsome J, McLeod C, Boland A, Davis H, Walley T, Dickson R
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
Dundar Y, Bagust A, Hounsome J, McLeod C, Boland A, Davis H, Walley T, Dickson R. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma. Health Technology Assessment 2009; 13(Suppl 1 Article 4): 23-28
Authors' conclusions
On balance the evidence indicates that R-CVP is more cost-effective than CVP.
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk